Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering

Business Wire January 30, 2020

Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

Business Wire January 29, 2020

Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial

Business Wire January 8, 2020

Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population

Business Wire December 16, 2019

Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress

Business Wire November 7, 2019

Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

Business Wire October 24, 2019

Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

Business Wire October 18, 2019

Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

Business Wire October 5, 2019

Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

Business Wire September 30, 2019

Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

Business Wire September 27, 2019

Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

Business Wire September 26, 2019

Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer

Business Wire September 25, 2019

Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress

Business Wire August 8, 2019

Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

Business Wire August 7, 2019

Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Business Wire August 6, 2019

Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th

Business Wire July 25, 2019

Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

Business Wire June 27, 2019

Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Business Wire June 21, 2019

Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference

Business Wire June 18, 2019

Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress

Business Wire May 14, 2019